TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status. (28th October 2021)

• Record Type: Journal Article
• Authors: Rahman, Fatima; Copson, Ellen; Hales, Alan; Rew, David
• Is Part Of: British journal of surgery. Volume 108:Supplement 7(2021)
• Publication Date: 2021-10-28
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjs/znab362.069
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Background: Breast neoplasia displays complex patterns of whole-of-life disease progression, which are difficult to study using legacy data systems. Our timeline- and episode-structured breast cancer data set of 20, 000 records allows direct visualisation of the entire documentary record of every patient. The embedded data mining module permits research into a wide range of patient cohorts by pathology, treatment and outcome. Methods: We selected the cohort of patients aged between 15 and 75 with HER-2 –ve and HER-2 +ve breast cancer who were treated with neoadjuvant chemotherapy (NAC), with or without anti-HER2 therapy between 2002 and 2019. We also studied the patterns and time intervals (in months) of disease progression and response to treatment from primary diagnosis, through loco-regional recurrence and distant metastasis to final outcome. Results: Of 301 women with confirmed early stage breast cancer were treated with NAC over that time, 186 had HER2- and 115 had HER2+ tumours. The patterns and intervals of disease progression, as displayed on the Master Lifetrack, were mapped and measured for every patient. The proportions of patients with Her2+ve tumours receiving trastuzumab and analogues, and the tumour responses to treatment, were audited. The underlying data set was validated by review of the original records. Conclusions: The whole-of-life timeline structured cancer data system introduces a new direction for clinical data visualisation, record management and user utility in surgical practice. This study validates the model as a tool for the better understanding of treatment effects and longitudinal behaviours in any selected range of cancer phenotypes.